Skip to main content
Top
Published in: Journal of Mammary Gland Biology and Neoplasia 4/2020

01-12-2020 | Obesity

Preclinical Models to Study Obesity and Breast Cancer in Females: Considerations, Caveats, and Tools

Authors: Erin D. Giles, Elizabeth A. Wellberg

Published in: Journal of Mammary Gland Biology and Neoplasia | Issue 4/2020

Login to get access

Abstract

Obesity increases the risk for breast cancer and is associated with poor outcomes for cancer patients. A variety of rodent models have been used to investigate these relationships; however, key differences in experimental approaches, as well as unique aspects of rodent physiology lead to variability in how these valuable models are implemented. We combine expertise in the development and implementation of preclinical models of obesity and breast cancer to disseminate effective practices for studies that integrate these fields. In this review, we share, based on our experience, key considerations for model selection, highlighting important technical nuances and tips for use of preclinical models in studies that integrate obesity with breast cancer risk and progression. We describe relevant mouse and rat paradigms, specifically highlighting differences in breast tumor subtypes, estrogen production, and strategies to manipulate hormone levels. We also outline options for diet composition and housing environments to promote obesity in female rodents. While we have applied our experience to understanding obesity-associated breast cancer, the experimental variables we incorporate have relevance to multiple fields that investigate women’s health.
Literature
1.
go back to reference Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284–91. PubMed Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284–91. PubMed
2.
go back to reference Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief. 2017;(288):1–8 Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief. 2017;(288):1–8
3.
go back to reference Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14. PubMedPubMedCentral Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14. PubMedPubMedCentral
4.
go back to reference Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14. PubMedPubMedCentral Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14. PubMedPubMedCentral
5.
go back to reference Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. 2015;1(5):611–21. PubMedPubMedCentral Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. 2015;1(5):611–21. PubMedPubMedCentral
6.
go back to reference Matthews SB, Thompson HJ. The obesity-breast cancer conundrum: an analysis of the issues. Int J Mol Sci. 2016;17(6):989. PubMedCentral Matthews SB, Thompson HJ. The obesity-breast cancer conundrum: an analysis of the issues. Int J Mol Sci. 2016;17(6):989. PubMedCentral
7.
go back to reference Chen L, Cook LS, Tang MT, Porter PL, Hill DA, Wiggins CL, et al. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Res Treat. 2016;157(3):545–54. PubMedPubMedCentral Chen L, Cook LS, Tang MT, Porter PL, Hill DA, Wiggins CL, et al. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Res Treat. 2016;157(3):545–54. PubMedPubMedCentral
8.
go back to reference Park YM, White AJ, Nichols HB, O’Brien KM, Weinberg CR, Sandler DP. The association between metabolic health, obesity phenotype and the risk of breast cancer. Int J Cancer. 2017;140(12):2657–66. PubMedPubMedCentral Park YM, White AJ, Nichols HB, O’Brien KM, Weinberg CR, Sandler DP. The association between metabolic health, obesity phenotype and the risk of breast cancer. Int J Cancer. 2017;140(12):2657–66. PubMedPubMedCentral
9.
go back to reference Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017;67(5):378–97. PubMedPubMedCentral Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017;67(5):378–97. PubMedPubMedCentral
10.
go back to reference Azvolinsky A. Cancer risk: the fat tissue-BMI-obesity connection. J Natl Cancer Inst. 2014;106(4):dju100. PubMed Azvolinsky A. Cancer risk: the fat tissue-BMI-obesity connection. J Natl Cancer Inst. 2014;106(4):dju100. PubMed
11.
go back to reference Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. PubMedPubMedCentral Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. PubMedPubMedCentral
12.
go back to reference Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. PubMed Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. PubMed
13.
go back to reference Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7. PubMedPubMedCentral Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7. PubMedPubMedCentral
14.
go back to reference Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. PubMed Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. PubMed
15.
go back to reference Heshmati K, Harris DA, Rosner B, Pranckevicius E, Ardestani A, Cho N, et al. Association of bariatric surgery status with reduced HER2+ breast cancers: a retrospective cohort study. Obes Surg. 2019;29(4):1092–8. PubMed Heshmati K, Harris DA, Rosner B, Pranckevicius E, Ardestani A, Cho N, et al. Association of bariatric surgery status with reduced HER2+ breast cancers: a retrospective cohort study. Obes Surg. 2019;29(4):1092–8. PubMed
16.
go back to reference Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, et al. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumabemtansine. Real-world evidence J Cell Physiol. 2020;235(11):7900–10. PubMed Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, et al. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumabemtansine. Real-world evidence J Cell Physiol. 2020;235(11):7900–10. PubMed
17.
go back to reference Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating tumor characteristics to the American joint committee on cancer breast cancer staging system. Oncologist. 2017;22(11):1292–300. PubMedPubMedCentral Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating tumor characteristics to the American joint committee on cancer breast cancer staging system. Oncologist. 2017;22(11):1292–300. PubMedPubMedCentral
18.
go back to reference Torres-de la Roche LA, Steljes I, Janni W, Friedl TWP, De Wilde RL. The association between obesity and premenopausal breast cancer according to intrinsic subtypes - a systematic review. Geburtshilfe Frauenheilkd. 2020;80(6):601–10. PubMedPubMedCentral Torres-de la Roche LA, Steljes I, Janni W, Friedl TWP, De Wilde RL. The association between obesity and premenopausal breast cancer according to intrinsic subtypes - a systematic review. Geburtshilfe Frauenheilkd. 2020;80(6):601–10. PubMedPubMedCentral
19.
go back to reference Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95. PubMedPubMedCentral Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95. PubMedPubMedCentral
20.
go back to reference Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–46. PubMedPubMedCentral Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–46. PubMedPubMedCentral
21.
go back to reference Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28(21):3411–5. PubMed Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28(21):3411–5. PubMed
22.
go back to reference Folkerd EJ, Dixon JM, Renshaw L, A’Hern RP, Dowsett M. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 2012;30(24):2977–80. PubMed Folkerd EJ, Dixon JM, Renshaw L, A’Hern RP, Dowsett M. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 2012;30(24):2977–80. PubMed
23.
go back to reference Ligibel JA, Winer EP. Aromatase inhibition in obese women: how much is enough? J Clin Oncol. 2012;30(24):2940–2. PubMed Ligibel JA, Winer EP. Aromatase inhibition in obese women: how much is enough? J Clin Oncol. 2012;30(24):2940–2. PubMed
24.
go back to reference Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex study group. Cancer. 1997;79(4):730–9. PubMed Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex study group. Cancer. 1997;79(4):730–9. PubMed
25.
go back to reference Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer. 1996;32A(3):404–12. PubMed Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer. 1996;32A(3):404–12. PubMed
26.
go back to reference Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, et al. Letrozole suppresses plasma estradiol and estronesulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26(10):1671–6. PubMed Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, et al. Letrozole suppresses plasma estradiol and estronesulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26(10):1671–6. PubMed
27.
go back to reference Elliott MJ, Ennis M, Pritchard KI, Townsley C, Warr D, Elser C, et al. Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. NPJ Breast Cancer. 2020;6:22. PubMedPubMedCentral Elliott MJ, Ennis M, Pritchard KI, Townsley C, Warr D, Elser C, et al. Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. NPJ Breast Cancer. 2020;6:22. PubMedPubMedCentral
28.
go back to reference Ozdemir BC, Sflomos G, Brisken C. The challenges of modeling hormone receptor-positive breast cancer in mice. Endocr Relat Cancer. 2018;25(5):R319–30. PubMed Ozdemir BC, Sflomos G, Brisken C. The challenges of modeling hormone receptor-positive breast cancer in mice. Endocr Relat Cancer. 2018;25(5):R319–30. PubMed
29.
go back to reference Welsch CW. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res. 1985;45(8):3415–43. PubMed Welsch CW. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res. 1985;45(8):3415–43. PubMed
30.
go back to reference Thompson HJ. Methods for the induction of mammary carcinogenesis in the rat using either 7,12-Dimethylbenz[α]anthracene or 1-Methyl-1-Nitrosourea. In: Ip M.M. ABB, editor. Methods in mammary gland biology and breast cancer research. Boston: Springer; 2000. p. 19–29. Thompson HJ. Methods for the induction of mammary carcinogenesis in the rat using either 7,12-Dimethylbenz[α]anthracene or 1-Methyl-1-Nitrosourea. In: Ip M.M. ABB, editor. Methods in mammary gland biology and breast cancer research. Boston: Springer; 2000. p. 19–29.
31.
go back to reference Thompson HJ, McGinley JN, Rothhammer K, Singh M. Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis. 1995;16(10):2407–11. PubMed Thompson HJ, McGinley JN, Rothhammer K, Singh M. Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis. 1995;16(10):2407–11. PubMed
32.
go back to reference Perse M, Cerar A, Injac R, Strukelj B. N-methylnitrosourea induced breast cancer in rat, the histopathology of the resulting tumours and its drawbacks as a model. Pathol Oncol Res. 2009;15(1):115–21. PubMed Perse M, Cerar A, Injac R, Strukelj B. N-methylnitrosourea induced breast cancer in rat, the histopathology of the resulting tumours and its drawbacks as a model. Pathol Oncol Res. 2009;15(1):115–21. PubMed
33.
go back to reference McCormick DL, Adamowski CB, Fiks A, Moon RC. Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea. Cancer Res. 1981;41(5):1690–4. PubMed McCormick DL, Adamowski CB, Fiks A, Moon RC. Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea. Cancer Res. 1981;41(5):1690–4. PubMed
34.
go back to reference MacLean PS, Giles ED, Johnson GC, McDaniel SM, Fleming-Elder BK, Gilman KA, et al. A surprising link between the energetics of ovariectomy-induced weight gain and mammary tumor progression in obese rats. Obesity (Silver Spring). 2010;18(4):696–703. MacLean PS, Giles ED, Johnson GC, McDaniel SM, Fleming-Elder BK, Gilman KA, et al. A surprising link between the energetics of ovariectomy-induced weight gain and mammary tumor progression in obese rats. Obesity (Silver Spring). 2010;18(4):696–703.
35.
go back to reference Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, et al. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res. 2012;72(24):6490–501. PubMedPubMedCentral Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, et al. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res. 2012;72(24):6490–501. PubMedPubMedCentral
36.
go back to reference Giles ED, Jindal S, Wellberg EA, Schedin T, Anderson SM, Thor AD, et al. Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res. 2018;20(1):50. PubMedPubMedCentral Giles ED, Jindal S, Wellberg EA, Schedin T, Anderson SM, Thor AD, et al. Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res. 2018;20(1):50. PubMedPubMedCentral
37.
go back to reference Giles ED, Jackman MR, MacLean PS. Modeling diet-induced obesity with obesity-prone rats: implications for studies in females. Front Nutr. 2016;3:50. PubMedPubMedCentral Giles ED, Jackman MR, MacLean PS. Modeling diet-induced obesity with obesity-prone rats: implications for studies in females. Front Nutr. 2016;3:50. PubMedPubMedCentral
38.
go back to reference Checkley LA, Rudolph MC, Wellberg EA, Giles ED, Wahdan-Alaswad RS, Houck JA, et al. Metformin accumulation correlates with organic cation transporter 2 protein expression and predicts mammary tumor regression in vivo. Cancer Prev Res (Phila). 2017;10(3):198–207. Checkley LA, Rudolph MC, Wellberg EA, Giles ED, Wahdan-Alaswad RS, Houck JA, et al. Metformin accumulation correlates with organic cation transporter 2 protein expression and predicts mammary tumor regression in vivo. Cancer Prev Res (Phila). 2017;10(3):198–207.
39.
go back to reference Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, et al. The androgen receptor supports tumor progression after the loss of ovarian function in a preclinical model of obesity and breast cancer. Horm Cancer. 2017;8(5–6):269–85. PubMedPubMedCentral Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, et al. The androgen receptor supports tumor progression after the loss of ovarian function in a preclinical model of obesity and breast cancer. Horm Cancer. 2017;8(5–6):269–85. PubMedPubMedCentral
40.
go back to reference Thompson HJ, McGinley JN, Wolfe P, Singh M, Steele VE, Kelloff GJ. Temporal sequence of mammary intraductal proliferations, ductal carcinomas in situ and adenocarcinomas induced by 1-methyl-1-nitrosourea in rats. Carcinogenesis. 1998;19(12):2181–5. PubMed Thompson HJ, McGinley JN, Wolfe P, Singh M, Steele VE, Kelloff GJ. Temporal sequence of mammary intraductal proliferations, ductal carcinomas in situ and adenocarcinomas induced by 1-methyl-1-nitrosourea in rats. Carcinogenesis. 1998;19(12):2181–5. PubMed
41.
go back to reference Thompson HJ, Adlakha H, Singh M. Effect of carcinogen dose and age at administration on induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis. 1992;13(9):1535–9. PubMed Thompson HJ, Adlakha H, Singh M. Effect of carcinogen dose and age at administration on induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis. 1992;13(9):1535–9. PubMed
42.
go back to reference Thompson HJ, Adlakha H. Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. Cancer Res. 1991;51(13):3411–5. PubMed Thompson HJ, Adlakha H. Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. Cancer Res. 1991;51(13):3411–5. PubMed
43.
go back to reference Hennighausen L. Mouse models for breast cancer. Oncogene. 2000;19(8):966–7. PubMed Hennighausen L. Mouse models for breast cancer. Oncogene. 2000;19(8):966–7. PubMed
44.
go back to reference Hutchinson JN, Muller WJ. Transgenic mouse models of human breast cancer. Oncogene. 2000;19(53):6130–7. PubMed Hutchinson JN, Muller WJ. Transgenic mouse models of human breast cancer. Oncogene. 2000;19(53):6130–7. PubMed
45.
go back to reference Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, et al. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Sci Adv. 2017;3(4):e1600957. PubMedPubMedCentral Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, et al. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Sci Adv. 2017;3(4):e1600957. PubMedPubMedCentral
46.
go back to reference Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228–41. PubMed Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228–41. PubMed
47.
go back to reference Evangelista GCM, Salvador PA, Soares SMA, Barros LRC, Xavier F, Abdo LM, et al. 4T1 Mammary carcinoma colonization of metastatic niches is accelerated by obesity. Front Oncol. 2019;9:685. PubMedPubMedCentral Evangelista GCM, Salvador PA, Soares SMA, Barros LRC, Xavier F, Abdo LM, et al. 4T1 Mammary carcinoma colonization of metastatic niches is accelerated by obesity. Front Oncol. 2019;9:685. PubMedPubMedCentral
48.
go back to reference Kirma NB, Tekmal RR. Transgenic mouse models of hormonal mammary carcinogenesis: advantages and limitations. J Steroid Biochem Mol Biol. 2012;131(3–5):76–82. PubMed Kirma NB, Tekmal RR. Transgenic mouse models of hormonal mammary carcinogenesis: advantages and limitations. J Steroid Biochem Mol Biol. 2012;131(3–5):76–82. PubMed
49.
go back to reference Usary J, Darr DB, Pfefferle AD, Perou CM. Overview of genetically engineered mouse models of distinct breast cancer subtypes. Curr Protoc Pharmacol. 2016;72:14 38 1-14 38 11. Usary J, Darr DB, Pfefferle AD, Perou CM. Overview of genetically engineered mouse models of distinct breast cancer subtypes. Curr Protoc Pharmacol. 2016;72:14 38 1-14 38 11.
50.
go back to reference Jallow F, Brockman JL, Helzer KT, Rugowski DE, Goffin V, Alarid ET, et al. 17beta-Estradiol and ICI182,780 differentially regulate STAT5 isoforms in female mammary epithelium, with distinct outcomes. J Endocr Soc. 2018;2(3):293–309. PubMedPubMedCentral Jallow F, Brockman JL, Helzer KT, Rugowski DE, Goffin V, Alarid ET, et al. 17beta-Estradiol and ICI182,780 differentially regulate STAT5 isoforms in female mammary epithelium, with distinct outcomes. J Endocr Soc. 2018;2(3):293–309. PubMedPubMedCentral
51.
go back to reference Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene. 2003;22(30):4664–74. PubMedPubMedCentral Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene. 2003;22(30):4664–74. PubMedPubMedCentral
52.
go back to reference Tilli MT, Frech MS, Steed ME, Hruska KS, Johnson MD, Flaws JA, et al. Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol. 2003;163(5):1713–9. PubMedPubMedCentral Tilli MT, Frech MS, Steed ME, Hruska KS, Johnson MD, Flaws JA, et al. Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol. 2003;163(5):1713–9. PubMedPubMedCentral
53.
go back to reference Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, et al. STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. Breast Cancer Res. 2012;14(1):R16. PubMedPubMedCentral Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, et al. STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. Breast Cancer Res. 2012;14(1):R16. PubMedPubMedCentral
54.
go back to reference Cardiff RD, Wellings SR. The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia. 1999;4(1):105–22. PubMed Cardiff RD, Wellings SR. The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia. 1999;4(1):105–22. PubMed
55.
go back to reference Fleming JM, Long EL, Ginsburg E, Gerscovich D, Meltzer PS, Vonderhaar BK. Interlobular and intralobular mammary stroma: genotype may not reflect phenotype. BMC Cell Biol. 2008;9:46. PubMedPubMedCentral Fleming JM, Long EL, Ginsburg E, Gerscovich D, Meltzer PS, Vonderhaar BK. Interlobular and intralobular mammary stroma: genotype may not reflect phenotype. BMC Cell Biol. 2008;9:46. PubMedPubMedCentral
56.
go back to reference Dankort DL, Muller WJ. Transgenic models of breast cancer metastasis. Cancer Treat Res. 1996;83:71–88. PubMed Dankort DL, Muller WJ. Transgenic models of breast cancer metastasis. Cancer Treat Res. 1996;83:71–88. PubMed
57.
go back to reference Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016;35(4):547–73. PubMedPubMedCentral Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016;35(4):547–73. PubMedPubMedCentral
58.
go back to reference Sflomos G, Dormoy V, Metsalu T, Jeitziner R, Battista L, Scabia V, et al. A preclinical model for ERalpha-Positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response. Cancer Cell. 2016;29(3):407–22. PubMed Sflomos G, Dormoy V, Metsalu T, Jeitziner R, Battista L, Scabia V, et al. A preclinical model for ERalpha-Positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response. Cancer Cell. 2016;29(3):407–22. PubMed
59.
go back to reference Matthews SB, Sartorius CA. Steroid hormone receptor positive breast cancer patient-derived xenografts. Horm Cancer. 2017;8(1):4–15. PubMed Matthews SB, Sartorius CA. Steroid hormone receptor positive breast cancer patient-derived xenografts. Horm Cancer. 2017;8(1):4–15. PubMed
60.
go back to reference Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, et al. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020;22(1):68. PubMedPubMedCentral Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, et al. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020;22(1):68. PubMedPubMedCentral
61.
go back to reference Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, et al. Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer. 2008;60(4):534–41. PubMed Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, et al. Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer. 2008;60(4):534–41. PubMed
62.
go back to reference Chumlea WC, Guo SS, Kuczmarski RJ, Flegal KM, Johnson CL, Heymsfield SB, et al. Body composition estimates from NHANES III bioelectrical impedance data. Int J Obes Relat Metab Disord. 2002;26(12):1596–609. PubMed Chumlea WC, Guo SS, Kuczmarski RJ, Flegal KM, Johnson CL, Heymsfield SB, et al. Body composition estimates from NHANES III bioelectrical impedance data. Int J Obes Relat Metab Disord. 2002;26(12):1596–609. PubMed
63.
go back to reference Kleinert M, Clemmensen C, Hofmann SM, Moore MC, Renner S, Woods SC, et al. Animal models of obesity and diabetes mellitus. Nat Rev Endocrinol. 2018;14(3):140–62. PubMed Kleinert M, Clemmensen C, Hofmann SM, Moore MC, Renner S, Woods SC, et al. Animal models of obesity and diabetes mellitus. Nat Rev Endocrinol. 2018;14(3):140–62. PubMed
64.
go back to reference Speakman J, Hambly C, Mitchell S, Krol E. The contribution of animal models to the study of obesity. Lab Anim. 2008;42(4):413–32. PubMed Speakman J, Hambly C, Mitchell S, Krol E. The contribution of animal models to the study of obesity. Lab Anim. 2008;42(4):413–32. PubMed
65.
go back to reference Tschop M, Heiman ML. Overview of rodent models for obesity research. Curr Protoc Neurosci. 2002;Chapter 9:Unit 9 10. Tschop M, Heiman ML. Overview of rodent models for obesity research. Curr Protoc Neurosci. 2002;Chapter 9:Unit 9 10.
66.
go back to reference Gunter MJ, Xie X, Xue X, Kabat GC, Rohan TE, Wassertheil-Smoller S, et al. Breast cancer risk in metabolically healthy but overweight postmenopausal women. Cancer Res. 2015;75(2):270–4. PubMedPubMedCentral Gunter MJ, Xie X, Xue X, Kabat GC, Rohan TE, Wassertheil-Smoller S, et al. Breast cancer risk in metabolically healthy but overweight postmenopausal women. Cancer Res. 2015;75(2):270–4. PubMedPubMedCentral
67.
go back to reference Kabat GC, Kim MY, Lee JS, Ho GY, Going SB, Beebe-Dimmer J, et al. Metabolic obesity phenotypes and risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2017;26(12):1730–5. PubMedPubMedCentral Kabat GC, Kim MY, Lee JS, Ho GY, Going SB, Beebe-Dimmer J, et al. Metabolic obesity phenotypes and risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2017;26(12):1730–5. PubMedPubMedCentral
68.
go back to reference Chlebowski RT, Aragaki AK, Anderson GL, Thomson CA, Manson JE, Simon MS, et al. Low-fat dietary pattern and breast cancer mortality in the women’s health initiative randomized controlled trial. J Clin Oncol. 2017;35(25):2919–26. PubMedPubMedCentral Chlebowski RT, Aragaki AK, Anderson GL, Thomson CA, Manson JE, Simon MS, et al. Low-fat dietary pattern and breast cancer mortality in the women’s health initiative randomized controlled trial. J Clin Oncol. 2017;35(25):2919–26. PubMedPubMedCentral
69.
go back to reference Chlebowski RT, Anderson GL, Manson JE, Prentice RL, Aragaki AK, Snetselaar L, et al. Low-fat dietary pattern and cancer mortality in the women’s health initiative (WHI) randomized controlled trial. JNCI Cancer Spectr. 2018;2(4):pky065. PubMed Chlebowski RT, Anderson GL, Manson JE, Prentice RL, Aragaki AK, Snetselaar L, et al. Low-fat dietary pattern and cancer mortality in the women’s health initiative (WHI) randomized controlled trial. JNCI Cancer Spectr. 2018;2(4):pky065. PubMed
70.
go back to reference Chlebowski RT, Aragaki AK, Anderson GL, Simon MS, Manson JE, Neuhouser ML, et al. Association of low-fat dietary pattern with breast cancer overall survival: a secondary analysis of the women’s health initiative randomized clinical trial. JAMA Oncol. 2018;4(10):e181212. PubMedPubMedCentral Chlebowski RT, Aragaki AK, Anderson GL, Simon MS, Manson JE, Neuhouser ML, et al. Association of low-fat dietary pattern with breast cancer overall survival: a secondary analysis of the women’s health initiative randomized clinical trial. JAMA Oncol. 2018;4(10):e181212. PubMedPubMedCentral
71.
go back to reference Chlebowski RT, Aragaki AK, Anderson GL, Pan K, Neuhouser ML, Manson JE, et al. Dietary modification and breast cancer mortality: long-term follow-up of the women’s health initiative randomized trial. J Clin Oncol. 2020;38(13):1419–28. PubMed Chlebowski RT, Aragaki AK, Anderson GL, Pan K, Neuhouser ML, Manson JE, et al. Dietary modification and breast cancer mortality: long-term follow-up of the women’s health initiative randomized trial. J Clin Oncol. 2020;38(13):1419–28. PubMed
72.
go back to reference Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, et al. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018;3(14):e120594. PubMedCentral Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, et al. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018;3(14):e120594. PubMedCentral
73.
go back to reference Giles ED, Jackman MR, Johnson GC, Schedin PJ, Houser JL, MacLean PS. Effect of the estrous cycle and surgical ovariectomy on energy balance, fuel utilization, and physical activity in lean and obese female rats. Am J Physiol Regul Integr Comp Physiol. 2010;299(6):R1634–42. PubMedPubMedCentral Giles ED, Jackman MR, Johnson GC, Schedin PJ, Houser JL, MacLean PS. Effect of the estrous cycle and surgical ovariectomy on energy balance, fuel utilization, and physical activity in lean and obese female rats. Am J Physiol Regul Integr Comp Physiol. 2010;299(6):R1634–42. PubMedPubMedCentral
74.
go back to reference Sherk VD, Jackman MR, Giles ED, Higgins JA, Foright RM, Presby DM, et al. Prior weight loss exacerbates the biological drive to gain weight after the loss of ovarian function. Physiol Rep. 2017;5(10):e13272. PubMedPubMedCentral Sherk VD, Jackman MR, Giles ED, Higgins JA, Foright RM, Presby DM, et al. Prior weight loss exacerbates the biological drive to gain weight after the loss of ovarian function. Physiol Rep. 2017;5(10):e13272. PubMedPubMedCentral
75.
go back to reference Sherk VD, Jackman MR, Higgins JA, Giles ED, Foright RM, Presby DM, et al. Impact of exercise and activity on weight regain and musculoskeletal health post-ovariectomy. Med Sci Sports Exerc. 2019;51(12):2465–73. PubMedPubMedCentral Sherk VD, Jackman MR, Higgins JA, Giles ED, Foright RM, Presby DM, et al. Impact of exercise and activity on weight regain and musculoskeletal health post-ovariectomy. Med Sci Sports Exerc. 2019;51(12):2465–73. PubMedPubMedCentral
76.
go back to reference Fischer AW, Cannon B, Nedergaard J. The answer to the question “What is the best housing temperature to translate mouse experiments to humans?” is: thermoneutrality. Mol Metab. 2019;26:1–3. PubMedPubMedCentral Fischer AW, Cannon B, Nedergaard J. The answer to the question “What is the best housing temperature to translate mouse experiments to humans?” is: thermoneutrality. Mol Metab. 2019;26:1–3. PubMedPubMedCentral
78.
go back to reference Keijer J, Li M, Speakman JR. What is the best housing temperature to translate mouse experiments to humans? Mol Metab. 2019a;25:168–76. PubMedPubMedCentral Keijer J, Li M, Speakman JR. What is the best housing temperature to translate mouse experiments to humans? Mol Metab. 2019a;25:168–76. PubMedPubMedCentral
79.
go back to reference Keijer J, Li M, Speakman JR. To best mimic human thermal conditions, mice should be housed slightly below thermoneutrality. Mol Metab. 2019b;26:4. PubMedPubMedCentral Keijer J, Li M, Speakman JR. To best mimic human thermal conditions, mice should be housed slightly below thermoneutrality. Mol Metab. 2019b;26:4. PubMedPubMedCentral
80.
go back to reference Speakman JR, Keijer J. Not so hot: Optimal housing temperatures for mice to mimic the thermal environment of humans. Mol Metab. 2012;2(1):5–9. PubMedPubMedCentral Speakman JR, Keijer J. Not so hot: Optimal housing temperatures for mice to mimic the thermal environment of humans. Mol Metab. 2012;2(1):5–9. PubMedPubMedCentral
81.
go back to reference Gordon CJ. Thermal physiology of laboratory mice: defining thermoneutrality. J Therm Biol. 2012;37(8):654–85. Gordon CJ. Thermal physiology of laboratory mice: defining thermoneutrality. J Therm Biol. 2012;37(8):654–85.
82.
go back to reference Morris EM, Noland RD, Allen JA, McCoin CS, Xia Q, Koestler DC, et al. Difference in housing temperature-induced energy expenditure elicits sex-specific diet-induced metabolic adaptations in mice. Obesity (Silver Spring). 2020;28(10):1922–31. Morris EM, Noland RD, Allen JA, McCoin CS, Xia Q, Koestler DC, et al. Difference in housing temperature-induced energy expenditure elicits sex-specific diet-induced metabolic adaptations in mice. Obesity (Silver Spring). 2020;28(10):1922–31.
83.
go back to reference Cui X, Nguyen NL, Zarebidaki E, Cao Q, Li F, Zha L, et al. Thermoneutrality decreases thermogenic program and promotes adiposity in high-fat diet-fed mice. Physiol Rep. 2016;4(10):e12799. PubMedPubMedCentral Cui X, Nguyen NL, Zarebidaki E, Cao Q, Li F, Zha L, et al. Thermoneutrality decreases thermogenic program and promotes adiposity in high-fat diet-fed mice. Physiol Rep. 2016;4(10):e12799. PubMedPubMedCentral
84.
go back to reference Hylander BL, Repasky EA. Thermoneutrality, mice, and cancer: A heated opinion. Trends Cancer. 2016;2(4):166–75. PubMed Hylander BL, Repasky EA. Thermoneutrality, mice, and cancer: A heated opinion. Trends Cancer. 2016;2(4):166–75. PubMed
85.
go back to reference Ravussin Y, LeDuc CA, Watanabe K, Leibel RL. Effects of ambient temperature on adaptive thermogenesis during maintenance of reduced body weight in mice. Am J Physiol Regul Integr Comp Physiol. 2012;303(4):R438–48. PubMedPubMedCentral Ravussin Y, LeDuc CA, Watanabe K, Leibel RL. Effects of ambient temperature on adaptive thermogenesis during maintenance of reduced body weight in mice. Am J Physiol Regul Integr Comp Physiol. 2012;303(4):R438–48. PubMedPubMedCentral
86.
go back to reference Stemmer K, Kotzbeck P, Zani F, Bauer M, Neff C, Muller TD, et al. Thermoneutral housing is a critical factor for immune function and diet-induced obesity in C57BL/6 nude mice. Int J Obes (Lond). 2015;39(5):791–7. Stemmer K, Kotzbeck P, Zani F, Bauer M, Neff C, Muller TD, et al. Thermoneutral housing is a critical factor for immune function and diet-induced obesity in C57BL/6 nude mice. Int J Obes (Lond). 2015;39(5):791–7.
87.
go back to reference Szymusiak R, Satinoff E. Maximal REM sleep time defines a narrower thermoneutral zone than does minimal metabolic rate. Physiol Behav. 1981;26(4):687–90. PubMed Szymusiak R, Satinoff E. Maximal REM sleep time defines a narrower thermoneutral zone than does minimal metabolic rate. Physiol Behav. 1981;26(4):687–90. PubMed
88.
go back to reference Neff EP. A point on thermoneutrality for mice. Lab Animal. 2020;49(6):169. Neff EP. A point on thermoneutrality for mice. Lab Animal. 2020;49(6):169.
89.
go back to reference Rogers NH, Perfield JW 2nd, Strissel KJ, Obin MS, Greenberg AS. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology. 2009;150(5):2161–8. PubMedPubMedCentral Rogers NH, Perfield JW 2nd, Strissel KJ, Obin MS, Greenberg AS. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology. 2009;150(5):2161–8. PubMedPubMedCentral
90.
go back to reference Witte MM, Resuehr D, Chandler AR, Mehle AK, Overton JM. Female mice and rats exhibit species-specific metabolic and behavioral responses to ovariectomy. Gen Comp Endocrinol. 2010;166(3):520–8. PubMedPubMedCentral Witte MM, Resuehr D, Chandler AR, Mehle AK, Overton JM. Female mice and rats exhibit species-specific metabolic and behavioral responses to ovariectomy. Gen Comp Endocrinol. 2010;166(3):520–8. PubMedPubMedCentral
91.
go back to reference Brooks HL, Pollow DP, Hoyer PB. The VCD mouse model of menopause and perimenopause for the study of sex differences in cardiovascular disease and the metabolic syndrome. Physiology (Bethesda). 2016;31(4):250–7. Brooks HL, Pollow DP, Hoyer PB. The VCD mouse model of menopause and perimenopause for the study of sex differences in cardiovascular disease and the metabolic syndrome. Physiology (Bethesda). 2016;31(4):250–7.
92.
go back to reference Van Kempen TA, Milner TA, Waters EM. Accelerated ovarian failure: a novel, chemically induced animal model of menopause. Brain Res. 2011;1379:176–87. PubMedPubMedCentral Van Kempen TA, Milner TA, Waters EM. Accelerated ovarian failure: a novel, chemically induced animal model of menopause. Brain Res. 2011;1379:176–87. PubMedPubMedCentral
93.
go back to reference Pearse G, Frith J, Randall KJ, Klinowska T. Urinary retention and cystitis associated with subcutaneous estradiol pellets in female nude mice. Toxicol Pathol. 2009;37(2):227–34. PubMed Pearse G, Frith J, Randall KJ, Klinowska T. Urinary retention and cystitis associated with subcutaneous estradiol pellets in female nude mice. Toxicol Pathol. 2009;37(2):227–34. PubMed
94.
go back to reference Dall G, Vieusseux J, Unsworth A, Anderson R, Britt K. Low dose, low cost estradiol pellets can support MCF-7 tumour growth in nude mice without bladder symptoms. J Cancer. 2015;6(12):1331–6. PubMedPubMedCentral Dall G, Vieusseux J, Unsworth A, Anderson R, Britt K. Low dose, low cost estradiol pellets can support MCF-7 tumour growth in nude mice without bladder symptoms. J Cancer. 2015;6(12):1331–6. PubMedPubMedCentral
95.
go back to reference Eyre R, Alferez DG, Spence K, Kamal M, Shaw FL, Simoes BM, et al. Patient-derived mammosphere and xenograft tumour initiation correlates with progression to metastasis. J Mammary Gland Biol Neoplasia. 2016;21(3–4):99–109. PubMedPubMedCentral Eyre R, Alferez DG, Spence K, Kamal M, Shaw FL, Simoes BM, et al. Patient-derived mammosphere and xenograft tumour initiation correlates with progression to metastasis. J Mammary Gland Biol Neoplasia. 2016;21(3–4):99–109. PubMedPubMedCentral
96.
go back to reference Levin-Allerhand JA, Sokol K, Smith JD. Safe and effective method for chronic 17beta-estradiol administration to mice. Contemp Top Lab Anim Sci. 2003;42(6):33–5. PubMed Levin-Allerhand JA, Sokol K, Smith JD. Safe and effective method for chronic 17beta-estradiol administration to mice. Contemp Top Lab Anim Sci. 2003;42(6):33–5. PubMed
97.
go back to reference Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007;13(13):3989–98. PubMed Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007;13(13):3989–98. PubMed
98.
go back to reference Scalzo RL, Foright RM, Hull SE, Knaub LA, Johnson-Murguia S, Kinanee F, et al. Breast cancer endocrine therapy exhausts adipocyte progenitors promoting weight gain and glucose intolerance. BioRxiv The Preprint Server for Biology. 2020. Scalzo RL, Foright RM, Hull SE, Knaub LA, Johnson-Murguia S, Kinanee F, et al. Breast cancer endocrine therapy exhausts adipocyte progenitors promoting weight gain and glucose intolerance. BioRxiv The Preprint Server for Biology. 2020.
99.
go back to reference Strom JO, Theodorsson A, Ingberg E, Isaksson IM, Theodorsson E. Ovariectomy and 17beta-estradiol replacement in rats and mice: a visual demonstration. J Vis Exp. 2012;64:e4013. Strom JO, Theodorsson A, Ingberg E, Isaksson IM, Theodorsson E. Ovariectomy and 17beta-estradiol replacement in rats and mice: a visual demonstration. J Vis Exp. 2012;64:e4013.
Metadata
Title
Preclinical Models to Study Obesity and Breast Cancer in Females: Considerations, Caveats, and Tools
Authors
Erin D. Giles
Elizabeth A. Wellberg
Publication date
01-12-2020
Publisher
Springer US
Published in
Journal of Mammary Gland Biology and Neoplasia / Issue 4/2020
Print ISSN: 1083-3021
Electronic ISSN: 1573-7039
DOI
https://doi.org/10.1007/s10911-020-09463-2

Other articles of this Issue 4/2020

Journal of Mammary Gland Biology and Neoplasia 4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine